{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:03:45Z","timestamp":1778864625631,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia and precursor to multiple myeloma. It has known ocular manifestations, but has not previously been shown to have an association with autoimmune retinopathy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 57\u2009year-old female presented with 1 year of progressive, bilateral, peripheral vision loss, photopsias, and nyctalopia. Her fundus examination and extensive ancillary testing were concerning for hereditary versus autoimmune retinopathy. The patient was found to have anti-retinal antibodies against carbonic anhydrase II and enolase proteins with a negative genetic retinal dystrophy panel. Malignancy work-up was negative, but the patient was diagnosed with MGUS, a premalignant condition. The patient was treated with immunosuppressive therapies, with rituximab demonstrating the most robust therapeutic response with respect to patient symptoms and ophthalmic testing.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>MGUS should be considered as a potential etiology of autoimmune retinopathy in patients without other autoimmune or malignant disease processes. Immunosuppressive therapy may be helpful in limiting disease progression, with rituximab showing efficacy in retinopathy refractory to other agents.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12886-020-01423-y","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T05:03:00Z","timestamp":1587013380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Autoimmune retinopathy associated with monoclonal gammopathy of undetermined significance: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Emily A.","family":"Eton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naheed W.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail T.","family":"Fahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"issue":"5","key":"1423_CR1","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1078-0432.CCR-12-2922","volume":"19","author":"A Agarwal","year":"2013","unstructured":"Agarwal A, Ghobrial I. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification and management of myeloma precursor disease. Clin Cancer Res. 2013;19(5):985\u201394.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1423_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241\u20139.","journal-title":"N Engl J Med"},{"key":"1423_CR3","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/j.jcjo.2013.07.018","volume":"48","author":"N Saffra","year":"2013","unstructured":"Saffra N, Rakhamimov A, Solomon WB, Scheers-Masters J. Monoclonal gammopathy of undetermined significance maculopathy. Can J Ophthalmol. 2013;48:e168\u201370.","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"1423_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3341\/kjo.2011.25.3.202","volume":"25","author":"H Koo","year":"2011","unstructured":"Koo H, Oh DH, Chun YS, Kim JC. A case of crystalline keratopathy in monoclonal gammopathy of undetermined significance (MGUS). Korean J Ophthalmol. 2011;25(3):202\u20135.","journal-title":"Korean J Ophthalmol"},{"key":"1423_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1590\/S0004-27492005000400021","volume":"68","author":"PF Tzelikis","year":"2005","unstructured":"Tzelikis PF, Laibson PR, Ribeiro MP, Rapuano CJ, Hammersmith KM, Cohen EJ. Ocular copper deposition associated with monoclonal gammopathy of undetermined significance: case report. Arq Bras Oftalmol. 2005;68:539\u201341.","journal-title":"Arq Bras Oftalmol"},{"key":"1423_CR6","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"1423_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3324\/haematol.2013.100552","volume":"99","author":"NW Van de Donk","year":"2014","unstructured":"Van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European myeloma network. Haematologica. 2014;99(6):984\u201396.","journal-title":"Haematologica."},{"key":"1423_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ajo.2013.09.019","volume":"157","author":"L Grange","year":"2014","unstructured":"Grange L, Dalal M, Nussenblatt RB, Sen HN. Autoimmune retinopathy. Am J Ophthalmol. 2014;157:266\u201372.","journal-title":"Am J Ophthalmol"},{"key":"1423_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00281-008-0114-7","volume":"30","author":"JR Heckenlively","year":"2008","unstructured":"Heckenlively JR, Ferreyra HA. Autoimmune retinopathy: a review and summary. Semin Immunopathol. 2008;30:127\u201334.","journal-title":"Semin Immunopathol"},{"key":"1423_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0039-6257(02)00416-2","volume":"48","author":"JW Chan","year":"2003","unstructured":"Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003;48:12\u201338.","journal-title":"Surv Ophthalmol"},{"key":"1423_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.survophthal.2012.09.001","volume":"58","author":"E Rahimy","year":"2013","unstructured":"Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. Surv Ophthalmol. 2013;58:430\u201358.","journal-title":"Surv Ophthalmol"},{"key":"1423_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/09273948.2014.884599","volume":"23","author":"Y Liu","year":"2015","unstructured":"Liu Y, Magro C, Loewenstein JI, Makar RS, Stowell CP, Dzik WH, et al. A man with paraneoplastic retinopathy plus small fiber polyneuropathy associated with Waldenstr\u00f6m macroglobulinemia (lymphoplasmacytic lymphoma): insights into mechanisms. Ocul Immunol Inflamm. 2015;23:405\u20139.","journal-title":"Ocul Immunol Inflamm"},{"key":"1423_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ophtha.2003.05.036","volume":"111","author":"HN Sen","year":"2004","unstructured":"Sen HN, Chan CC, Caruso RC, Fariss RN, Nussenblatt RB, Buggage RR. Waldenstr\u00f6m\u2019s macroglobulinemia\u2013associated retinopathy. Ophthalmology. 2004;111:535\u20139.","journal-title":"Ophthalmology."},{"key":"1423_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bbacli.2016.05.004","volume":"6","author":"A Shimanovsky","year":"2016","unstructured":"Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016;6:12\u20138.","journal-title":"BBA Clin"},{"key":"1423_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/IAE.0000000000000119","volume":"34","author":"DA Grewal","year":"2014","unstructured":"Grewal DA, Fishman GA, Jampol LM. Autoimmune retinopathy and antiretinal antibodies: a review. Retina. 2014;34:827\u201345.","journal-title":"Retina."},{"key":"1423_CR16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/archophthalmol.2009.24","volume":"127","author":"HA Ferreyra","year":"2009","unstructured":"Ferreyra HA, Jayasundera T, Khan NW, He S, Lu Y, Heckenlively JR. Management of autoimmune retinopathies with immunosuppression. Arch Ophthalmol. 2009;127:390\u20137.","journal-title":"Arch Ophthalmol"},{"issue":"13","key":"1423_CR17","first-page":"2517","volume":"55","author":"DA DiLoreto","year":"2014","unstructured":"DiLoreto DA, Williams Z, Khalifa YM. Autoimmune retinopathy treated with the fluocinolone acetonide intravitreal implant after intolerance to systemic immunosuppression. Invest Ophthalmol Vis Sci. 2014;55(13):2517.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1423_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ajo.2017.04.019","volume":"180","author":"S Davoudi","year":"2017","unstructured":"Davoudi S, Ebrahimiadib N, Yasa C, Sevgi DD, Roohipoor R, Papavasilieou E, et al. Outcomes in autoimmune retinopathy patients treated with rituximab. Am J Ophthalmol. 2017;180:124\u201332.","journal-title":"Am J Ophthalmol"},{"key":"1423_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13023-017-0680-7","volume":"12","author":"K Boudreault","year":"2017","unstructured":"Boudreault K, Justus S, Sengillo JD, Schuerch K, Lee W, Cabral T, et al. Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy. Orphanet J Rare Dis. 2017;12:129.","journal-title":"Orphanet J Rare Dis"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01423-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01423-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01423-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T01:11:30Z","timestamp":1618535490000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01423-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1423"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01423-y","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"21 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional Review Board approval was not required for this manuscript according to institutional guidelines. The patient consented to participate orally and in writing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this article and accompanying images. A copy of the written consent is available for review on request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}